Korean J Hematol.  2011 Jun;46(2):96-102. 10.5045/kjh.2011.46.2.96.

Treatment outcomes in children with Burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution

• Park ES
• Kim H
• Lee JW
• Lim JY
• Kang HJ
• Park KD
• Shin HY
• Ahn HS

• KMID: 1782773
• DOI: http://doi.org/10.5045/kjh.2011.46.2.96

Abstract

BACKGROUND
We compared the outcomes of patients with Burkitt lymphoma and French-American-British (FAB) L3 acute lymphoblastic leukemia treated using Lymphoma Malignancy B (LMB) or other treatment protocols.
METHODS
Thirty-eight patients diagnosed between July 1996 and December 2007 were treated using LMB 96, and 22 patients diagnosed between January 1991 and May 1998 (defined as the early period) were treated using the D-COMP or CCG-106B protocols. We retrospectively reviewed their medical records and analyzed cumulative survival according to the treatment period by using Kaplan-Meier analysis.
RESULTS
There were no intergroup differences in the distribution of age, disease stage, or risk group. The median follow-up period of the 33 live patients in the LMB group was 72 months (range, 36-170 months). Overall survival (OS) and event-free survival (EFS) of patients treated using LMB 96 were 86.8%+/-5.5% and 81.6%+/-6.3%, respectively, whereas OS and EFS of patients treated in the early period were 72.7%+/-9.6% and 68.2%+/-9.9%, respectively. In the LMB 96 group, OS of cases showing non-complete response (N=8) was 62.5%+/-17.1%, and OS of relapsed or primary refractory cases (N=6) was 33.3%+/-19.3%. Central nervous system (CNS) disease, high lactate dehydrogenase levels at diagnosis, and treatment response were significant prognostic factors.
CONCLUSION
Survival outcome has drastically improved over the last 2 decades with short-term, dose-intensive chemotherapy. However, CNS involvement or poor response to chemotherapy was worse prognostic factors; therefore, future studies addressing this therapeutic challenge are warranted.

Keyword

Burkitt lymphoma; L3 lymphocytic leukemia; Treatment outcome; Prognosis

MeSH Terms

Burkitt Lymphoma
Central Nervous System
Child
Disease-Free Survival
Follow-Up Studies
Humans
L-Lactate Dehydrogenase
Lymphoma
Medical Records
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognosis
Retrospective Studies
Treatment Outcome
L-Lactate Dehydrogenase

Figure

• 

  Fig. 1 LMB 96 protocol schedule [8]. Patients were stratified into 3 risk groups: A, B, and C, depending on stage, resection status, percentage of blasts in BM, and CNS involvement. Group A: Resected stage I and abdominal stage II. Group B: Patients not eligible for inclusion in group A or C. Group C: Patient with CNS involvement and more than 70% of blast in bone marrow. In the LMB 96 protocol, cranial irradiation was skipped and replaced with high-dose methotrexate (MTX) between consolidation phases in patients with CNS-positive disease.

• 

  Fig. 2 Outcome in patients treated using the LMB protocol. Three patients showed relapse (RL) after complete response (CR), and 2 of them responded to salvage therapy and are alive with no evidence of disease. Cases that did not show CR after the first consolidation chemotherapy included 5 cases of partial response (PR) and 3 refractory (ref) cases. One case of toxic death occurred during induction chemotherapy.

• 

  Fig. 3 Survival outcome of patients treated using LMB 89 (1996-2007) (A), and according to protocols used in the early period (1990-1998) (B).

• 

  Fig. 4 Event-free survival according to stage (A), treatment risk group (B), and LDH levels (C).

• 

  Fig. 5 Comparative analysis of event-free survival (EFS) according to the involvement of bone marrow. EFS of patients treated using the LMB protocol (A) and D-COMP or 106B protocols (B). In the early period, differences in EFS between groups with or without bone marrow involvement were significant (P=0.01). However, the differences between these groups were not significant in patients treated using the LMB protocol.

• 

  Fig. 6 Comparative analysis of event-free survival (EFS) according to the involvement of the central nervous system (CNS). EFS of patients treated using the LMB protocol (A) and D-COMP or 106B protocols (B). In either treatment group, there was no significant difference in EFS between groups with or without CNS involvement.

Reference

1. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med. 1996; 334:1238–1248. PMID: 8606720.

2. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol. 2000; 18:3707–3721. PMID: 11054444.

3. Patte C, Philip T, Rodary C, et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol. 1986; 4:1219–1226. PMID: 3525767.

4. Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991; 9:123–132. PMID: 1985161.

5. Gentet JC, Patte C, Quintana E, et al. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol. 1990; 8:661–665. PMID: 2313335.

6. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007; 109:2736–2743. PMID: 17138821.

7. Park ES, Kim SD, Kang HJ, Choi HS, Shin HY, Ahn HS. Treatment of B-cell acute lymphoblastic leukemia and B-cell lymphoma. Korean J Pediatr Hematol Oncol. 2002; 9:166–176.

8. Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001; 97:3370–3379. PMID: 11369626.

9. Meadows AT, Sposto R, Jenkin RD, et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol. 1989; 7:92–99. PMID: 2642543.

10. Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol. 1993; 11:2234–2242. PMID: 8229139.

11. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7:332–339. PMID: 7414342.

12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50:163–170. PMID: 5910392.

13. Atra A, Gerrard M, Hobson R, Imeson JD, Hann IM, Pinkerton CR. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol. 2001; 112:965–968. PMID: 11298592.

14. Attarbaschi A, Dworzak M, Steiner M, et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer. 2005; 44:70–76. PMID: 15368550.

15. Fujita N, Mori T, Mitsui T, Inada H, Horibe K, Tsurusawa M. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer. 2008; 51:188–192. PMID: 18428432.

16. Won SC, Han JW, Kwon SY, et al. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: a report from the Korean society of pediatric hematology-oncology. Ann Hematol. 2006; 85:787–794. PMID: 16932891.

17. Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009; 52:177–181. PMID: 18816698.

18. Attias D, Weitzman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr. 2008; 20:17–22. PMID: 18197034.

19. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007; 109:2773–2780. PMID: 17132719.